Clinical Trial Update: Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating valproate in combination with doxorubicin in malignant mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Valproate (valproate)

Snippet

Sponsor: European Lung Cancer Working Party | Conditions: Malignant Mesothelioma | Phase 2 | Status: COMPLETED